Opus Genetics, Inc.
IRD
Rank in Stocks
#14027
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on... Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Share Price
$4.20
Last synced: 2026-11-09
Market Cap
$349.42M
Change (1 day)
0.48%
Change (1 year)
113.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Opus Genetics, Inc. (IRD)
Category
Healthcare
EPS for Opus Genetics, Inc. (IRD)
EPS as of June 2026 TTM: $-1.27
According to Opus Genetics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.27. At the end of 2025 the company had an EPS of $-0.80, an increase over its 2024 EPS of $-2.15.
EPS history for Opus Genetics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.27 | 58.75% |
| 2025 | $-0.80 | -62.79% |
| 2024 | $-2.15 | 367.39% |
| 2023 | $-0.46 | -151.11% |
| 2022 | $0.90 | -123.56% |
| 2021 | $-3.82 | -27.65% |
| 2020 | $-5.28 | 506.90% |
| 2019 | $-0.87 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,333.07% |
US
|
|
| $-7.07 | 456.69% |
US
|
|
| $-5.29 | 316.54% |
AU
|
|
| $12.88 | -1,114.18% |
BE
|
|
| $21.56 | -1,797.64% |
NL
|
Questions about Opus Genetics, Inc.'s earnings per share (EPS)
What is Opus Genetics, Inc.'s earnings per share (EPS)?
Opus Genetics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.27, as of Jun 2026.
What was Opus Genetics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Opus Genetics, Inc.'s earnings per share (EPS) was $-0.80, compared with $-2.15 in 2024.
How has Opus Genetics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Opus Genetics, Inc.'s earnings per share (EPS) was highest in 2022 ($0.90) and lowest in 2020 ($-5.28).
How does Opus Genetics, Inc.'s earnings per share (EPS) compare with similar companies?
Opus Genetics, Inc.'s earnings per share (EPS) ($-1.27) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.